Group 1 - The company holds an 11.1111% stake in New Anjin [2] - New Anjin's individualized drug injection P01 is currently advancing clinical trials as planned [2]

Group 1 - The core point of the article is the progress of clinical trials for Nuanzin's personalized drug injection P01, which is the world's first personalized tumor neoantigen peptide vaccine approved by both Chinese and American drug regulatory authorities [2][3] - New Source (300109.SZ) holds an 11.1111% stake in Nuanzin and has confirmed that the clinical trials for P01 are progressing as planned [2] - The company emphasizes its commitment to timely, fair, and significant information disclosure in compliance with legal obligations [2]

Core Insights - On November 25, several companies disclosed share buybacks, while 14 A-share listed companies announced share reductions, indicating mixed market sentiment regarding stock ownership [1][2]. Buyback Activities - Jingtenda increased its stake by 0.71% [2] - China Energy Conservation plans to increase its stake in Wanrun Co. [2] - Yishitong intends to repurchase shares worth between 20 million to 45 million yuan [2] - Shiji Huatu obtained a commitment letter for a stock repurchase loan from China Merchants Bank, not exceeding 900 million yuan [2] - Geji Co. plans to repurchase shares worth between 50 million to 70 million yuan [2] Share Reduction Activities - Bid Medical plans to reduce its stake by up to 0.16% [4] - Ziyuan Food's shareholders intend to reduce their holdings by up to 0.67% [4] - Kaipu Testing's shareholder Li Yaping plans to reduce his stake by up to 1% [4] - Hemai Co. plans to reduce its stake by up to 3% [4] - New Open Source's directors and executives plan to reduce their holdings by up to 0.05% [4] - Jingbeifang's deputy general manager plans to reduce his stake by up to 0.0021% [4] - Xiangnong Xinchuan's directors and executives plan to reduce their holdings by up to 270,000 shares [4] - *ST Xingguang's director Zhang Taohua plans to reduce his stake by up to 0.05% [4] - Chenxi Aviation's controlling shareholder Huiju Technology plans to reduce its stake by up to 3% [4] - Zhongchen Co.'s controlling shareholder plans to reduce its stake by up to 3% [4] - Zhongfu Shenying's shareholder Eagle Group plans to reduce its stake by up to 1% [4] - Luxiao Technology's controlling shareholder and actual controller plan to reduce their holdings by up to 3% [4] - Yidian Tianxia's second-largest shareholder reduced its holdings by 13.9712 million shares from October 28 to November 25 [4]

（编辑 姚尧） 证券日报网讯 11月25日晚间，新开源发布公告称，截至本公告日持有博爱新开源医疗科技集团股份有 限公司（以下简称"公司"或"本公司"）股份525，000股（占本公司总股本比例0.11%）的董事、高级管 理人员于江涛先生计划在本公告披露之日起15个交易日后的3个月内（2025年12月17日至2026年03月16 日，但窗口期不减持）以集中竞价交易方式减持公司股份不超过（含）130，000股（占公司总股本的比 例不超过0.03%）。截至本公告日持有公司股份352，500股（占本公司总股本比例0.07%）的高级管理 人员邢小亮先生计划在本公告披露之日起15个交易日后的3个月内（2025年12月17日至2026年03月16 日，但窗口期不减持）以集中竞价交易方式减持公司股份不超过（含）88，000股（占公司总股本的比 例不超过0.02%） ...

Core Viewpoint - The announcement details the planned share reduction by two senior executives of Xin Kai Yuan (300109.SZ), indicating a potential shift in insider sentiment towards the company's stock [1] Group 1: Share Reduction Plans - Director Jiang Tao plans to reduce his holdings by up to 130,000 shares, which represents no more than 0.03% of the company's total share capital, within a specified window from December 17, 2025, to March 16, 2026, excluding any reduction during the trading window [1] - Senior executive Xing Xiaoliang intends to reduce his holdings by up to 88,000 shares, accounting for no more than 0.02% of the company's total share capital, also within the same trading window [1]

Group 1 - The company New Open Source (SZ 300109) announced that two executives plan to reduce their shareholdings within three months, with one executive intending to sell up to 130,000 shares (0.03% of total shares) and another up to 88,000 shares (0.02% of total shares) [1] - As of the announcement date, the company holds approximately 520,000 shares (0.11% of total shares) by one executive and 352,500 shares (0.07% of total shares) by another [1] - For the first half of 2025, the company's revenue composition is 89.56% from fine chemicals and 10.44% from medical services [1] Group 2 - The company's market capitalization is reported to be 8.7 billion yuan [2] - A related company, identified as 688496, is under investigation by the Securities Regulatory Commission due to a significant loss exceeding 100 million yuan shortly after its listing, with its main customer reducing procurement [2]

Core Viewpoint - The company announced that two senior executives plan to reduce their shareholdings due to personal financial needs, with specific limits on the number of shares to be sold and assurances that this will not affect the company's control or governance structure [1] Group 1: Shareholding Reduction Plans - Executive Jiang Tao plans to reduce his holdings by up to 130,000 shares, representing no more than 0.03% of the total share capital, within three months after a 15 trading day period from the announcement [1] - Executive Xing Xiaoliang intends to reduce his holdings by up to 88,000 shares, accounting for no more than 0.02% of the total share capital, also within three months after the 15 trading day period [1] Group 2: Current Shareholding Status - As of the announcement date, Jiang Tao holds 525,000 shares, which is 0.11% of the total share capital [1] - As of the announcement date, Xing Xiaoliang holds 352,500 shares, which is 0.07% of the total share capital [1] Group 3: Conditions and Implications - The share reduction plans are based on personal financial needs and the shares are sourced from equity incentives [1] - The planned reductions do not violate any relevant commitments and will not lead to changes in company control or affect its governance structure and ongoing operations [1]

Core Points - The company announced that its board member and senior vice president, Yu Jiangtao, holds 525,000 shares, accounting for 0.11% of total shares, and plans to reduce his holdings by up to 130,000 shares (0.03%) through centralized bidding from December 17, 2025, to March 16, 2026 [1] - The company’s board secretary and vice president, Xing Xiaoliang, holds 352,500 shares, representing 0.07% of total shares, and intends to reduce his holdings by up to 88,000 shares (0.02%) during the same period [1]

证券代码：300109 证券简称：新开源 公告编号：2025-040 博爱新开源医疗科技集团股份有限公司 关于部分董事、高级管理人员股份减持计划的预披露公告 董事、高级管理人员于江涛先生、高级管理人员邢小亮先生保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至本公告日持有博爱新开源医疗科技集团股份有限公司（以下简称"公司" 或"本公司"）股份 525,000 股（占本公司总股本比例 0.11%）的董事、高级管 理人员于江涛先生计划在本公告披露之日起 15 个交易日后的 3 个月内（2025 年 12 月 17 日至 2026 年 03 月 16 日，但窗口期不减持）以集中竞价交易方式减持 公司股份不超过（含）130,000 股（占公司总股本的比例不超过 0.03%）。 截至本公告日持有公司股份 352,500 股（占本公司总股本比例 0.07%）的高 级管理人员邢小亮先生计划在本公告披露之日起15个交易日后的3个月内（2025 年 12 月 17 日至 2026 年 03 月 16 日，但窗口 ...

Market Overview - As of 10:31 AM today, the Shanghai Composite Index is at 3876.57 points, above the six-month moving average, with an increase of 1.04% [1] - The total trading volume of A-shares today is 853.41 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 382 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Tonghe Technology (300491) with a deviation rate of 9.12% and a price increase of 10.01% [1] - Xunxing Co., Ltd. (002098) with a deviation rate of 9.03% and a price increase of 10.04% [1] - Laimu Co., Ltd. (603633) with a deviation rate of 7.04% and a price increase of 7.90% [1] Additional Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Longyuan Technology (not specified) and Newcapec (not specified) with minor deviations [1] - Other stocks with notable performance include: - Hongbai New Materials (605366) with a deviation rate of 6.77% and a price increase of 7.26% [1] - Kecuan Technology (603052) with a deviation rate of 5.50% and a price increase of 10.00% [1]